

# Survey on Hepatitis vaccine shortage among VHPB advisors

March 2018



### **Questions Survey**

#### **Hepatitis A vaccine**

- Is there currently a hepatitis A vaccination shortage: Yes/No
- since:
- until:
- which type:
- Brand:
- Is there currently a Hepatitis A outbreak in which risk groups
- Are there prioritisation guidelines created
- Is there a need for prioritisation guidelines?

#### **Hepatitis B**

- Is there currently a hepatitis B vaccination shortage: Yes/No
- since:
- until:
- which type:
- Brand:
- Are there prioritisation guidelines created
- Is there a need for prioritisation guidelines?



### VHPB Advisors







WHO-Euro



WHO



Erika Duffell **ECDC** 



**Andrew Amato ECDC** 



John Ward CDC



Fiona Godfrey EASL



Tatjana Reic ELPA



Hans Blystad Norway



**David Goldberg** Scotland



Bulgaria



Mira Kojouharova Johannes Hallauer Germany



Silvia Bino Albania



#### VHPB Advisors







Vladimir Chulanov Russia



Angela Dominguez Spain



Wolfgang Jilg Germany



Helène Norder Sweden



Vana Papaevangelou Greece



Mojca Maticic Slovenia



Françoise Roudot-Thoraval France



Rui Tato Morinho Portugal




Daniel Shouval Israel



Alessandro Zanetti Italy



#### Shortage Hepatitis A



	Country	since	Until	Туре	Brand
	Belgium	4/2017	15/07/2018	Havarix	GSK Not for Sanofi
	Bulgaria				
,	Croatia	Last moths	?	Havarix	GSK
- - -	France	11/2016		Havrix1440 (adult)	GSK/ MSD
)	Greece	12/2017	05/2018	Pediatric (Vaqta) Ped/adult	MSD Not for GSK
	Israel	12/2017	02/2018	Monovalent HAV	HAVrix GSK
	Italy	02/2018 01/2018	05/2018	Avaxim Havrix	Sanofi GSK
וכאמרורוס	Norway	Autum/2017		Adult dose	Havrix(GSK) Vaqta(Sanofi) Avax
<u> </u>	Portugal				
	Russia				
	Slovenia	GSK replaced by Sanofi			
	UK	Mid 2017	?	Hep monovalent	
	USA	Summer '17	Spring '18	Merck production suspended	GSK unable to increase production

Country	since	Until		Туре	Brand
Belgium	4/2017		- there is one more hep A vaccine from Merck: Vaqta and Vaqta Junior (25U) is no longer		
Bulgaria					
Croatia	Last moths	?	available since 10/7/2017 till 31/5/2018. the adult form of Vaqta is availablepediatric form of Avaxim is not on the market in		
France	11/2016				on the market in
Greece	12/2017	05/20	Belgium  Greec	e: limited amount	of GSK
Israel	12/2017	02/20	months		out in coming
Italy	02/2018 01/2018	05/20			
Norway	Autum/2017			Adult dose	Havrix(GSK) Vaqta(Sanofi) Avax
Portugal					
Russia				There is an increase in in MSM and interesting	•
Slovenia	GSK replaced by Sanofi	child	vaccination, mostly in MSM and, interestingly enough, in children (ie in January 2018 instead of usual 50 vaccines per month, there were 150 children vaccinated). No shortage of GSK combined HAV+HBV vaccine (Twinrix) was observed.		al 50 vaccines
UK	Mid 2017				ne (Twinrix)
USA	Summer '17	Spring	g '18	Merck production suspended	GSK unable to increase production


	Country	outbreak	Guidelines	Need for guidelines
	Belgium	No	No	Usefull
	Bulgaria	No	No	Yes
	Croatia			
	France	No (sporadic cases)	Yes (since 03/17)	No
	Greece	No (sporadic cases)	No	
	Israel	No	Yes	Yes
	Italy	No	No	Usefull
	Norway	Small in MSM	Yes	Usefull on national level not EU
•	Portugal			
	Russia	28 outbreaks of HAV registered		NO
	Slovenia	No	No	NO
	UK	Outbreak linked to food	yes	
	USA	Substance users/ Homeless	Yes	YES

#### recommendations

- France: guidelines for Haut conseil de la santé publicqueA
- ISrael: Recommended to use of Havrix only for second dose, Recommended two simultaneous doses of Havrix Junior Until Havrix adult available (Both dose forms of Havrix are currently available, returned to Standard immunization procedures. Would be willing to consider uk Guidelines of Using Havrix)
- Norway: MSM and close contacts to cases prioritised. Alternative for travel related vaccination published: 1. Use of Twinrix 2. Use of Havrix720 EU (child dose) at 0,1 and 6-12 months for adults (off-label)
- (Italy During 2017 epidemics of hepatitis A, vaccination was primarly reccommended to people at higher risk (MSM) and to close contacts with patient with hepatitis A)
- USA



#### Shortage Hepatitis B



	Country
	Belgium
	Bulgaria
e	Croatia
ccir	France
acc	Greece
>	Israel
tis B	Italy
<b>:</b>	Norway
og	Portugal
e	Russia
工	Slovenia
	UK
	USA

Country	since	Until	Туре
Belgium	06/2017 09/2017	03/2018 06/2018	Engerix 20µg HBVaxPro 10ug Twinrix
Bulgaria			
Croatia	Since a year but replace product		
France			
Greece	06/2017	05/2018	MSD adult HBVaxPro 10mcg/1r
Israel			
Italy	05/2017 02/2017 05/2017	02/2018 04/2018	Engerix 20µg HBVaxPro 10ug Twinrix
Norway			
Portugal			
Russia			
Slovenia	GSK replaced by Sanofi		
UK	June 2017	Summer 2018	HBV monovalent
USA	12/2017	Adult	one manufacture adult - through 2018; pediatric April 1, 2018

adult MSD No shortage for GSK xPro 10mcg/1ml rix 20µg GSK xPro 10ug MSD No shortage rix monovalent manufacturer -Merck

**Brand** 

No shortage

GSK

MSD

	Country	since	Until	Туре	Brand
	Belgium	06/2017 09/2017	03/2018 06/2018	Engerix 20µg HBVaxPro 10ug Twinrix	GSK MSD No shortage
	Bulgaria				
ובלשנונוס ה אשרכווום	Croatia	Since a year but replaced product			
	France				
	Greece	06/2017	05/2018	MSD adult HBVaxPro 10mcg/1ml	MSD No shortage for GSK
	Israel				
	Italy	05/2017 02/2017 05/2017	02/2018 04/2018	Engerix 20µg HBVaxPro 10ug Twinrix	GSK MSD No shortage
	Norway			Slovenia: The authorities would like to increase a supply for the year 2018 compared to the year 2017, however both GSK and Merck could provide only the amount mentioned in the previous year. To avoid possible future shortages, contracts have been already signed for the 2019 and	
<u>ک</u>	Portugal				
ש	Russia				
_	Slovenia	GSK replaced by Sanofi		2020 suplies.	a for the 2013 and
	UK	June 2017	Summer 2018		
	USA	12/2017	Adult	one manufacturer - adult - through 2018; pediatric April 1, 2018	Merck

vaccine
lepatitis B v
H

	Country			
	Belgium			
	Bulgaria			
<u>)</u>	Croatia			
	France			
<b>)</b>	Greece			
)	Israel			
	Italy			
2	Norway			
)	Portugal			
-	Russia			
	Slovenia			
	UK			
	USA			

Guidelines

No

No

No

No

No

No

No

No

Yes

adequate

No - supply from other manufacturer

Yes, created in

march 2017, have been removed since March 1st 2018

**Need for** 

Usefull

Yes

NO

Usefull

No

NO

Not so

Not at this time

**Guidelines** 

**Comments** 

manufacturers.

FAGG, Belgian Regulatory Agency has all information on non-

Limited amount-possible stock out in the following months

The vaccine needs are covered mainly by two domestic

Dialysis formulation not affected

availability of drugs and vaccins on her website:

<u> </u>	
<b>&gt;</b>	
)	
֡֝֝֝֝֡֜֝֓֓֓֓֓֝֝֓֓֓֓֡֝֡֜֝֓֡֓֡֡֝֡֡֜֜֝֓֡֓֡֡֡֡֝֡֓֡֡֡֡֡֡֓֡֓֡֓֡֡֡֡֡֡֡֡	
2	
<u> </u>	
_	

•	ロロコンのハ	ノロンロハ
	Υ	
	I	ر -

## Company information

(source: National Drug regulatory agencies and manufacturers)

Hepatitis A					
MSD Sharp & Dohme GmbH	Hepatitis A vaccine (virus vaccine, inactivated)	Available again mid June'18			
GSK	Havrix Adult	Restored capacity 2018			
GSK	Havrix Junior	June'18			
<b>Hepatitis</b> B					
GSK	Engerix (paediatric/ Adult)	Resolved – return to historic volume during 2018 (due to increase demand shortage 17 constraints expected in 2018			
Merck	Hepatitis adult Paediatric	End 2018 April 2018			



## Conclusion end 2017 after first survey

- There are supply related constrains on securing access
  - Mentioned by companies and countries
  - Difficult to assess real consequences due to limited information
  - No supply issues in the WHO EURO Region in the recent years for HBV new situation
  - Country specific HBV vaccine supply challenges (some countries yes, other no!)
- Need for recommendations specific for managing supply issues
  - (cfr. ECDC recommendations for pertussis Ag containing vaccine shortages)
  - Some NITAG made such product specific recommendations for HAV/HBV vaccines
  - Centralized emergency stock (at level of EU, WHO EURO, companies ...)
  - Have companies guaranteeing supply every 6 months, or switch tendere to competitor
  - Room for VHPB to draft guidelines to assist countries in making such recommendations

